» Articles » PMID: 30760082

Association Between Norepinephrine Levels and Abnormal Iron Status in Patients With Chronic Heart Failure: Is Iron Deficiency More Than a Comorbidity?

Abstract

Background Mechanisms underlying iron homeostasis dysregulation in patients with chronic heart failure remain unsettled. In cardiomyocyte models, norepinephrine may lead to intracellular iron depletion, but the potential association between catecholamines (sympathetic activation markers) and iron metabolism biomarkers in chronic heart failure is unknown. Methods and Results In this cross-sectional analysis, we studied the association between plasma norepinephrine levels and serum iron status biomarkers indicating iron storage (ferritin), iron transport (transferrin saturation), and iron demand (soluble transferrin receptor) in a prospective cohort of 742 chronic heart failure patients (mean age, 72±11 years; 56% male). Impaired iron status was defined as ferritin <100 μg/L or transferrin saturation <20%. Impaired iron status was observed in 69% of patients. In multivariate models, greater norepinephrine levels were associated with impaired iron transport (transferrin saturation <20%, odds ratio=2.28; 95% CI [1.19-4.35]; P=0.013), but not with impaired iron storage (ferritin <100 μg/L, odds ratio=1.25; 95% CI [0.73-2.16]; P=0.415). Norepinephrine was a significant predictor of increased iron demand (soluble transferrin receptor, standardized β-coefficient=0.12; P=0.006) and low transferrin saturation (standardized β-coefficient=-0.12; P=0.003). However, norepinephrine levels were not associated with iron or ferritin levels ( P>0.05). Adjusted norepinephrine marginal means were significantly higher in patients with impaired iron status compared with those with normal iron status (528 pg/mL [505-551] versus 482 pg/mL [448-518], respectively; P=0.038). Conclusions In chronic heart failure patients, increased sympathetic activation estimated with norepinephrine levels is associated with impaired iron status and, particularly, dysregulation of biomarkers suggesting impaired iron transport and increased iron demand. Whether the relationship between norepinephrine and iron metabolism is bidirectional and entails causality need to be elucidated in future research.

Citing Articles

The role of genetically predicted serum iron levels on neurodegenerative and cardiovascular traits.

Belbellaj W, Lona-Durazo F, Bodano C, Busseuil D, Cyr M, Fiorillo E Sci Rep. 2024; 14(1):24588.

PMID: 39427026 PMC: 11490554. DOI: 10.1038/s41598-024-76245-9.


Empagliflozin effects on iron metabolism as a possible mechanism for improved clinical outcomes in non-diabetic patients with systolic heart failure.

Angermann C, Santos-Gallego C, Requena-Ibanez J, Sehner S, Zeller T, Gerhardt L Nat Cardiovasc Res. 2024; 2(11):1032-1043.

PMID: 39196095 PMC: 11358002. DOI: 10.1038/s44161-023-00352-5.


Identification of three mechanistic pathways for iron-deficient heart failure.

Packer M, Anker S, Butler J, Cleland J, Kalra P, Mentz R Eur Heart J. 2024; 45(26):2281-2293.

PMID: 38733250 PMC: 11231948. DOI: 10.1093/eurheartj/ehae284.


Soluble Transferrin Receptor as Iron Deficiency Biomarker: Impact on Exercise Capacity in Heart Failure Patients.

Ras-Jimenez M, Ramos-Polo R, Francesch Manzano J, Corbella Santano M, Morillas Climent H, Jose-Bazan N J Pers Med. 2023; 13(8).

PMID: 37623532 PMC: 10455097. DOI: 10.3390/jpm13081282.


Psychosocial factors partially explain gender differences in health-related quality of life in heart failure patients.

Tapia J, Basalo M, Enjuanes C, Calero E, Jose N, Ruiz M ESC Heart Fail. 2022; 10(2):1090-1102.

PMID: 36582154 PMC: 10053343. DOI: 10.1002/ehf2.14260.


References
1.
Moliner P, Enjuanes C, Tajes M, Cainzos-Achirica M, Lupon J, Garay A . Association Between Norepinephrine Levels and Abnormal Iron Status in Patients With Chronic Heart Failure: Is Iron Deficiency More Than a Comorbidity?. J Am Heart Assoc. 2019; 8(4):e010887. PMC: 6405646. DOI: 10.1161/JAHA.118.010887. View

2.
Bayeva M, Ardehali H . Mitochondrial dysfunction and oxidative damage to sarcomeric proteins. Curr Hypertens Rep. 2010; 12(6):426-32. DOI: 10.1007/s11906-010-0149-8. View

3.
Ponikowski P, Voors A, Anker S, Bueno H, Cleland J, Coats A . 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special.... Eur Heart J. 2016; 37(27):2129-2200. DOI: 10.1093/eurheartj/ehw128. View

4.
Van Aelst L, Abraham M, Sadoune M, Lefebvre T, Manivet P, Logeart D . Iron status and inflammatory biomarkers in patients with acutely decompensated heart failure: early in-hospital phase and 30-day follow-up. Eur J Heart Fail. 2017; 19(8):1075-1076. DOI: 10.1002/ejhf.837. View

5.
Packer M, Bristow M, Cohn J, Colucci W, Fowler M, Gilbert E . The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996; 334(21):1349-55. DOI: 10.1056/NEJM199605233342101. View